Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT04724031
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
Sponsor: Hellenic Cooperative Oncology Group
View on ClinicalTrials.gov
Summary
Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.
Key Details
Gender
FEMALE
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
180
Start Date
2019-11-01
Completion Date
2025-04-30
Last Updated
2026-10-19
Healthy Volunteers
Not specified
Conditions
Interventions
DRUG
PARP inhibitor
use at any line of treatment in patients with advanced ovarian cancer
Locations (1)
Adamantia Nikolaidi
Athens, Attica, Greece